SEOUL - In the wake of the recent divestment of its stake in smaller rival Ildong Pharmaceutical Co. Ltd., Green Cross Corp., which specializes in the development and manufacturing of plasma derivatives, vaccines, recombinant proteins, therapeutic antibodies and cell therapies, is now looking outside the country for possible acquisitions to grow and beef up its R&D pipelines.
"We would prefer to acquire foreign firms, unless a particularly good candidate emerges at home. We are primarily looking at...